These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9044313)

  • 61. Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries.
    Lin CL; Wang FS; Kuo YR; Huang YT; Huang HC; Sun YC; Kuo YH
    Kidney Int; 2006 May; 69(9):1593-600. PubMed ID: 16572112
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus.
    Berg TJ; Bangstad HJ; Torjesen PA; Osterby R; Bucala R; Hanssen KF
    Metabolism; 1997 Jun; 46(6):661-5. PubMed ID: 9186302
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Advanced glycation end products and diabetic complications.
    Stitt AW; Jenkins AJ; Cooper ME
    Expert Opin Investig Drugs; 2002 Sep; 11(9):1205-23. PubMed ID: 12225243
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Extracellular matrix in human diabetic nephropathy: reduced expression of heparan sulphate in skin basement membrane.
    van der Pijl JW; Daha MR; van den Born J; Verhagen NA; Lemkes HH; Bucala R; Berden JH; Zwinderman AH; Bruijn JA; van Es LA; van der Woude FJ
    Diabetologia; 1998 Jul; 41(7):791-8. PubMed ID: 9686920
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Loganin attenuates diabetic nephropathy in C57BL/6J mice with diabetes induced by streptozotocin and fed with diets containing high level of advanced glycation end products.
    Liu K; Xu H; Lv G; Liu B; Lee MK; Lu C; Lv X; Wu Y
    Life Sci; 2015 Feb; 123():78-85. PubMed ID: 25623853
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Alterations of glomerular matrix proteins in the pathogenesis of diabetic nephropathy.
    Olgemöller B; Schleicher E
    Clin Investig; 1993; 71(5 Suppl):S13-9. PubMed ID: 8518535
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Advanced glycation end-products in diabetic nephropathy.
    Friedman EA
    Nephrol Dial Transplant; 1999; 14 Suppl 3():1-9. PubMed ID: 10382974
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Advanced glycation end products.
    Thomas MC
    Contrib Nephrol; 2011; 170():66-74. PubMed ID: 21659759
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Histological localization of advanced glycosylation end products in the progression of diabetic nephropathy.
    Imai N; Nishi S; Suzuki Y; Karasawa R; Ueno M; Shimada H; Kawashima S; Nakamaru T; Miyakawa Y; Araki N; Horiuchi S; Gejyo F; Arakawa M
    Nephron; 1997; 76(2):153-60. PubMed ID: 9200406
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Nodular lesions and mesangiolysis in diabetic nephropathy.
    Wada T; Shimizu M; Yokoyama H; Iwata Y; Sakai Y; Kaneko S; Furuichi K
    Clin Exp Nephrol; 2013 Feb; 17(1):3-9. PubMed ID: 23100177
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Paeoniflorin ameliorates AGEs-induced mesangial cell injury through inhibiting RAGE/mTOR/autophagy pathway.
    Chen J; Zhao D; Zhu M; Zhang M; Hou X; Ding W; Sun S; Bu W; Feng L; Ma S; Jia X
    Biomed Pharmacother; 2017 May; 89():1362-1369. PubMed ID: 28320103
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Advanced glycation end products and diabetic nephropathy: a comparative study using diabetic and normal rats with methylglyoxal-induced glycation.
    Rodrigues L; Matafome P; Crisóstomo J; Santos-Silva D; Sena C; Pereira P; Seiça R
    J Physiol Biochem; 2014 Mar; 70(1):173-84. PubMed ID: 24078283
    [TBL] [Abstract][Full Text] [Related]  

  • 73. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
    Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
    Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
    [TBL] [Abstract][Full Text] [Related]  

  • 74. In situ localization of type III and type IV collagen-expressing cells in human diabetic nephropathy.
    Razzaque MS; Koji T; Taguchi T; Harada T; Nakane PK
    J Pathol; 1994 Oct; 174(2):131-8. PubMed ID: 7965408
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy.
    Wang SN; LaPage J; Hirschberg R
    Kidney Int; 2000 Mar; 57(3):1002-14. PubMed ID: 10720953
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nodular lesions in diabetic nephropathy: Collagen staining and renal prognosis.
    Mise K; Ueno T; Hoshino J; Hazue R; Sumida K; Yamanouchi M; Hayami N; Suwabe T; Hiramatsu R; Hasegawa E; Sawa N; Fujii T; Hara S; Wada J; Makino H; Takaichi K; Ohashi K; Ubara Y
    Diabetes Res Clin Pract; 2017 May; 127():187-197. PubMed ID: 28388509
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pathophysiological role of Amadori-glycated proteins in diabetic microangiopathy.
    Schalkwijk CG; Lieuw-a-Fa M; van Hinsbergh VW; Stehouwer CD
    Semin Vasc Med; 2002 May; 2(2):191-7. PubMed ID: 16222610
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Advanced glycation end products and diabetic nephropathy.
    Thomas MC; Forbes JM; Cooper ME
    Am J Ther; 2005; 12(6):562-72. PubMed ID: 16280650
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Advanced glycation end products and the kidney.
    Bohlender JM; Franke S; Stein G; Wolf G
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F645-59. PubMed ID: 16159899
    [TBL] [Abstract][Full Text] [Related]  

  • 80. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.
    Nakamura S; Tachikawa T; Tobita K; Aoyama I; Takayama F; Enomoto A; Niwa T
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S68-71. PubMed ID: 12612956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.